- Home
- EXEL vs VERA Comparison
EXEL vs VERA Comparison
Compare EXEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | VERA |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 1.5B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EXEL | VERA |
|---|---|---|
| Price | $46.23 | $53.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 11 |
| Target Price | $45.18 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 2.6M | 1.9M |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.55 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,288,218,000.00 | N/A |
| Revenue This Year | $9.84 | N/A |
| Revenue Next Year | $11.92 | N/A |
| P/E Ratio | $19.57 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $31.90 | $18.53 |
| 52 Week High | $49.62 | $56.05 |
Technical Indicators
Market Signals| Indicator | EXEL | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 80.23 |
| Support Level | $40.83 | $47.22 |
| Resistance Level | $47.24 | $56.05 |
| Average True Range (ATR) | 1.27 | 2.89 |
| MACD | 0.40 | 0.39 |
| Stochastic Oscillator | 84.57 | 85.61 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.